Lilly buys California diabetes biotech in deal potentially worth $1 billion
The Indianapolis-based drugmaker said the deal to buy Protomer Technologies could be worth up to $1 billion if the technology meets certain milestones. Lilly did not say how much it was paying up front in cash.